Thank you very much for the submission of your research manuscript to our editorial office. We have now received the full set of reports from the referees that were asked to assess it.
Thank you very much for the submission of your research manuscript to our editorial office. We have now received the full set of reports from the referees that were asked to assess it.
While all reviewers agree in principle on the interesting nature of the observations reported here, they also point out a number of instances in which the data would need to be strengthened before publication. The most important point raised by referee 1 (and also commented on by the other two reviewers) is that stronger data for the inhibition of translation elongation versus initiation should be provided and the referees provide suggestions on how this could be achieved. The other issues raised are rather minor and in most instances only require additional clarifications and/or discussions.
Given the potential interest of your study and the constructive suggestions of the reviewers on how to improve it, I would like to give you the opportunity to revise your manuscript, with the understanding that the main concerns of the referees must be addressed and their suggestions taken on board. Acceptance of the manuscript will depend on a positive outcome of a second round of review and I should also remind you that it is EMBO reports policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript.
I would also like to point out that we now strongly encourage the publication of original source data (whole western blots and raw microscopical images) with the aim of making primary data more accessible and transparent to the reader. The source data will be published in a separate source data file online along with the accepted manuscript and will be linked to the relevant figure. As one of the referees also raised this issue, I would strongly recommend that you send us these raw data when submitting your revised manuscript.
I look forward to seeing a revised form of your manuscript when it is ready.
REFEREE REPORTS
Referee #1:
In the manuscript by De Gassart et al the authors describe an interesting outcome of the application of a HIV-protease inhibitor (NFR) in human and mouse cell lines -namely the activation of the eEF2 kinase. This complements previous work on the NFR inhibitor and begins to uncover its mode of action as an anticancer therapeutic. These observations are novel and will be of interest to cancer and signal-transduction biologists. Exposure to NFR induces a robust induction of eEF2 phosphorylation, which the authors demonstrate is independent of upstream AMPK or mTORC1 regulation, as well as separating the eEF2K activation from the integrated stress response. Genetic manipulation of the eEF2K gene in multiple cell lines demonstrates that the effect of NFR is at least in part dependent upon eEF2K expression. Finally the authors transplant tumour cells into mice and show that eEF2K-/-tumours are less responsive to NFR than wild-type control tumours.
Major concerns: 1. There is little evidence to convince the reader that NFR is impacting translation elongation, despite the large induction of eEF2 phosphorylation. The methionine labelling ( Figure 4A ) illustrates the expected reduction in protein synthesis but the polysome traces are insufficient to provide any mechanistic insight into how this is occurring on their own. Indeed, from the traces it would appear that an initiation block is more likely the cause of reduced protein synthesis. The authors account for this by suggesting eEF2 may play a part in initiation, where in truth further experiments are required. The authors should directly measure the rate of translation elongation by ribosome half transit times and/or harringtonine run-off analysis. This would greatly improve the manuscript and remove doubt as to the mechanism of action of NFR. Polysome traces from cells where eEF2K has been activated by an alternative mechanism (e.g. rapamycin) would also allow comparison to the traces following NFR treatment. These polysome traces also omit the free 40S subunit peak, which makes the polysome:subpolysomes ratio data presented difficult to interpret. Why has the trace been presented like this?
2. The premise for analysis of eEF2K activation is not fully explained. The lead result that eEF2K mRNA and protein is reduced by NFR seems distant from the rest of the manuscript which analyses activation of eEF2K protein. eEF2K mRNA and protein expression is known to change under stress, and as a response to eEF2K activation. Perhaps the authors are observing a similar effect here? Similarly, eEF2K shows a modest 1.5 fold reduction in the RNAseq data, with hundreds of other transcripts showing greater modulation. Among these transcripts it is noted that translation initiation factors and nucleolar proteins are present. Is it possible that these also contribute to the reduction in protein synthesis? Was any other validation of the RNAseq data carried out?
3. The role of eEF2K downstream of NFR is described with multiple methods by the authors. However some of these methods also show that in the absence of eEF2K NFR is still able to slow growth or reduce viability of cells. Furthermore, there is a modest 20% increase in EC50 in eEF2K-/-cells compared to wild-type, suggesting that the drug is able to inhibit cell growth at only a slightly lower concentration in the presence of eEF2K. This implies that although eEF2K is important following NFR treatment that alternative mechanisms are also participating in NFR antitumour activity. The authors therefore need to take care in over-stating their conclusions.
4.The manuscript states that NFR was used at 10µM to generate resistant clones and later at 10µM, 20µM or 40µM NFR to analyse effects on signalling. However, in most figure panels the concentration of NFR is annotated in mM not µM. Could the authors clarify the concentration of NFR used.
Minor points: 1. The authors do not address a multitude of mechanisms by which eEF2K can be activated, such as by calcium ion influx or by cyclin B or ERK signalling. It is appreciated that analysis of these pathways is beyond the scope of the present work but to state that 'NFR signals eEF2K activation independent of known eEF2K activating pathways' requires discussion of these modes of regulation.
2. Changes in protein expression or phosphorylation are at times reported without mention of repeat experiments and statistical analysis of the differences. This is of particular concern in: Figure 1D how reduced is the expression of eEF2K protein? It appears to be reduced beyond the modest reduction in mRNA. Figure 2C -clone 1 does not appear to have reduced eEF2-P compared to the control. Is this the case? How much is the reduction in clones 2 and 3?
3. In Figure 6B there appears to be a band for eEF2-P in the eEF2K-/-cell lines. Which band is the one of interest?
4. Appendix figure S2 does not contain data from wild-type cells to compare the eIF2α S51A cells too. The main text implies that this has been done so the data should be included or text re-written. 5. The context the manuscript is written from makes it difficult to follow at times. It would seem more appropriate to discuss the incidences of eEF2K activation as an anti-cancer therapeutic (as this manuscript shows for NFR), rather than leading with the literature focused on eEF2K suppression as a means to target tumours. An excellent job in writing about both angles is presented but it seems that the focus could be shifted towards the literature that is most closely related to this story rather than the contradictory (but entirely correct in certain contexts) view of e Referee #2:
In this interesting study the authors show that inhibitors of the HIV aspartyl protease activate eEF2K and inhibit eEF2. Cells resistant to eEF2 overcome the anti-tumour effects of this drug which are mediated through this pathway.
The experiments are in general well performed and support the claims made.
A few additional experiments are requested to address a couple of points Figure 4 . A) Rather than using autoradiography to show a reduction in protein synthesis scintillation counting should be used. Then it would be possible to show significance of the effect. The reduction with tunicamycin looks rather unconvincing. Alternatively the radiography could be repeated 3X and the data shown graphically. B) As pointed out in the manuscript if the inhibition of translation was solely due to elongation changes there should be no difference in the heavy polysomes and indeed there should have been an increase in the heavy fractions on the polysomes as the mRNAs are stalled. I think that the unexpected effect is due to the fact that both initiation and elongation are inhibited by NFR. Indeed, it is shown in the EV figures that there is a significant phosphorylation of eIF2 alpha which would also inhibit initiation. To show that while both processes are inhibited it is elongation that drives the protein synthesis shutdown a couple more experiments are required. 1. Add NFR to cells that have been transfected with the dominant negative version of GADD34 (this will dephosphorylated eIF2 alpha), Then repeat the gradients and use met labelling to show that despite eIF2 activation this isn't sufficient to restore protein synthesis rates. 2. Add NFR in the presence of ISRIB, this should phenocopy the GADD34 experiment.
Minor point Please don't use protein translation. proteins are synthesised and mRNAs are translated. e.g.in the abstract "protein translation elongation rates' should read mRNA translation elongation rates etc, Referee #3:
In this study, Dr. Martinon and colleagues have investigated the oncology mechanism of action of the drug Nelfinavir and show that it includes the ability to activate eEF2K, leading to the phosphorylation of eEF2 which causes its inactivation. eEF2 participates in translation elongation but is inhibited when phosphorylated and thereby slows translation elongation rates. Much of the study is well done but there are several issues that need to be resolved as outlined below.
1. The major criticism of the work presented is that it does not connect he established activity of Nelfinavir directly to molecular mechanisms. Early on in the study the authors show that drug treatment strongly reduces the mRNA levels for eEF2K ( Figure 1C ), but they never revisit this important effect and never explain or investigate how it occurs. This appears to be a major effect of the drug yet it is never followed up.
2. It is unclear why any of the traditional signaling to eEF2K protein would be expected to alter its mRNA levels. Why was the mTOR pathway explored? How does this connect?
3. The fact that eF2 phosphorylation does not alter polysome profiles significantly at the level of elongation still needs explanation. The suggestion that an alternate activity of eF2 phosphorylation, the splitting of 80S ribosomes (which are often inactive) does not directly address the mechanism of action of the drug nor how it would reduce cell proliferation.
4. The authors need to more fully explain how they conducted drug resistance studies. Important details are not described. How long was the election for, at what doses? How was it ascertained that resistance arose? Were these clonal or mixed populations of cells? We submit our revised manuscript "Promoting cell death and antitumor activity by increasing eEF2K activation" (MS#: EMBOR-2016-42194-T) for your consideration for publication in EMBO reports. We appreciate the opportunity to submit a revised version of the manuscript addressing the thoughtful and constructive comments of the reviewers and editors, which we have tried to respond to fully. Accordingly, the revised manuscript includes several new pieces of data addressing reviewer's questions and comments that we think strengthen the significance of the study. Importantly, we provided new data demonstrating the role of eEF2K in regulating translation rates beyond elongation. Major changes to the manuscript text have been noted in red in the uploaded marked-up version of the manuscript.
Please let us know if we need to provide additional information as you reconsider the revised manuscript.
Point-by-point reply to the specific points raised by the Editor We agree with the reviewer comments and performed the suggested experiments. We analyzed translation elongation by ribosome half transit time measurements in WT and eEF2K KO MEFs treated with NFR. We used starvation and low doses of cycloheximide as positive controls. We found that NFR augmented translation elongation times in an eEF2K-dependent manner. These new data are included in New Figure 4D and discussed in the paper.
As recommended by the referee, we also monitored polysomal profiling in presence of rapamycin. Despite a block in 35S-Methionine incorporation (see New Figure 4B ), we did not observe a robust effect on the polysome profile (New Figure EV4C ). In this setup, rapamycin is predicted to regulate both initiation and elongation, two mechanisms that may compensate each other on the polysomal profile. Moreover in these cells, treatment with rapamycin only weakly activates eEF2 phophorylation (see Figure 2B lane 4) and eEF2K does not contribute significantly to overall block of protein synthesis (see New Figure 4B ). We therefore used low doses of cycloheximide as a positive control that exerts its effect by interfering with the translocation step in protein synthesis. In presence of cycloheximide, as expected, we detected an increase of the polysomal fraction (New Figure EV4C ).
Importantly our data show that NFR mediated decrease of the polysomal fraction is eEF2K dependent ( Figure 4C ), but not dependent on the phosphorylation of the initiation factor eIF2a (New Figure EV4A and EV4B). On the other hand eEF2K deficiency does not affect tunicamycin-mediated translation inhibition ( Figure 4C ). We also demonstrate that eEF2K is not required for eIF2a phosphorylation ( Figure EV2A ), further suggesting that these two pathways are independent one of the other. Altogether these results indicate that NFRmediated eEF2K activation triggers an accumulation of the subpolysomal fraction while decreasing the polysomal fraction.
These findings indicate that eEF2K has additional functions beyond its role in regulating elongation. In yeast eEF2 phosphorylation has been proposed to play a role in termination or initiation by promoting the splitting of the 80S ribosomes into subunits (1). It is therefore possible that eEF2 has additional functions. However whether such mechanism could contribute to eEF2K-mediated decrease of the polysomal fraction in presence of NFR, is not known.
We did not omit the free 40S subunit peak in our polysomal analysis, but in these cells the 40S did not resolve well and was not reproducibly detected (see also New Figure EV4 ). To confirm the presence of 40S subunit in the fraction, considered in the analysis as the "subpolysomal fraction (S)", we performed RNA analysis of fractions collected from our polysomal profile to monitor 28s and 18s rRNA. We used WT MEFs and the same conditions as used in the manuscript except that we had to load more extracts to be able to monitor rRNA on a RNA gel. Because the 40S only contains 18S rRNA, we could identify the fraction containing the 40S (fraction n°7, see attached figure below). Even if this fraction appears to be minor compared to the 80S and 60S ribosomal peaks, we are now sure that it was integrated in our P/S ratio measurement. In the experiment presented in Figure 1 , we analyzed clones that acquired resistance to NFR and observed that eEF2K was consequently reduced. Among the overall cell population treated with the drug only a few clones deployed mechanism of resistance and our RNAseq analysis revealed that all the tested clones shared a decrease in eEF2K expression. Because these clones survive and proliferate for months in presence of NFR while parental cells die within a few days, we hypothesized that this pathway could contribute to NFR-mediated toxicity. We also showed that these clones have increased ATF4 activation and integrated stress response as evidenced by the RNA-seq data. Nevertheless, if we remove NFR from the media for a few hours the integrated stress response is lost, and can be fully re-activated by treatment with NFR (Fig. EV3B, 3C ). In contrast, in same conditions EEF2K activity was irreversibly reduced, in accordance with decreased eEF2K expression, and correlated with decreased eEF2 phosphorylation in presence of NFR (Fig 1D, 2C ).
We realized that this was confusing in the manuscript and revised this section to clarify this point. To better address the reviewer comment, we also present new data that show that long-term treatment with NFR is not directly required for downregulation of eEF2K expression in the clones (New Fig EV1) . We monitored eEF2K expression after NFR washout from the culture and observed that two out of three clones maintained eEF2K downregulation for weeks while one clone regained eEF2K expression after a few days in absence of NFR. This indicates that the mechanism engaged by the clones to bypass eEF2K -mediated toxicity are multiple and can be maintained even in absence of NFR.
Similarly, eEF2K shows a modest 1.5 fold reduction in the RNAseq data, with hundreds of other transcripts showing greater modulation. Among these transcripts it is noted that translation initiation factors and nucleolar proteins are present. Is it possible that these also contribute to the reduction in protein synthesis? Was any other validation of the RNAseq data carried out?
The reviewer is correct, when we analyze the RNA-seq data for genes downregulated in the clones, factors involved in ribonucleoprotein complex biogenesis and translation regulation are among the top categories identified by gene ontology searches. This indicated that these clones adapted their translation machinery. Whether these genes could be eventually regulated upstream, downstream or independently of eEF2K and could contribute to survival upon treatment with NFR remains to be explored and will be a good source of inspiration for future work. Nevertheless, we focused the study on eEF2K because this well established stress response pathway is known to respond to changes in cellular homeostasis and has therefore the capacity to integrate changes in environment to modify translation programs. We did not study how and if eEF2K contributes to the regulation of these genes and if these genes are involved in NFR-mediated inhibition of protein synthesis, however we revised the result section to clarify this and included this observation.
The role of eEF2K downstream of NFR is described with multiple methods by the authors. However some of these methods also show that in the absence of eEF2K NFR is still able to slow growth or reduce viability of cells. Furthermore, there is a modest 20% increase in EC50 in eEF2K-/-cells compared to wild-type, suggesting that the drug is able to inhibit cell growth at only a slightly lower concentration in the presence of eEF2K. This implies that although eEF2K is important following NFR treatment that alternative mechanisms are also participating in NFR antitumour activity. The authors therefore need to take care in over-stating their conclusions.
We agree with the reviewer that other alternative mechanisms are also participating in NFR mediated cell death; this is particularly true at higher doses of the drug. However among all the pathways that have been proposed to be activated by NFR, eEF2K is the only one we found to be impacting on cell viability. We revised the manuscript and rephrased some sentences possibly over-stating the data. We apologize for this. We did not notice that upon building the PDF µM were changed for mM. This has been corrected in the revised version. We appreciate this comment and revised this section of the discussion adding hypothesis and references to other possible mechanisms by which eEF2K could be regulated. We included quantification of multiple experiments for Figure 1D and New Figure EV3A . According to these WB quantifications, reduction in p-EEF2 can reach up to 75% in clone 2 and 3 and is indeed less significant for clone 1. Interestingly, long-term NFR washout experiment (New Figure EV1) revealed that the phenotype of eEF2K reduced level decreases in clone 1 while it remains robust for the other clones tested.
Changes in protein expression
We clarified this in the figure. Precise analysis of the Molecular Weight and comparison of the signals obtained with p-eEF2 and Total-eEF2 specific antibodies allowed us to identify p-eEF2 as the upper band on the WB. Note that we analyzed the full tumor, therefore components of the tumor environment may account for the small p-eEF2 signal observed in the eEF2K KO tumors.
We also included original source data with the Molecular Weight for all Western blots in the Figures.
Appendix figure S2 does not contain data from wild-type cells to compare the eIF2α S51A cells too. The main text implies that this has been done so the data should be included or text re-written.
We included the data for the littermate eIF2α S51WT cells. This panel is now included in New Figure EV4B .
The context the manuscript is written from makes it difficult to follow at times. It would seem more appropriate to discuss the incidences of eEF2K activation as an anti-cancer therapeutic (as this manuscript shows for NFR), rather than leading with the literature focused on eEF2K suppression as a means to target tumours. An excellent job in writing about both angles is presented but it seems that the focus could be shifted towards the literature that is most closely related to this story rather than the contradictory (but entirely correct in certain contexts) view of e
As suggested by the reviewer we rewrote the introduction to focus on the anti-cancer therapeutic angle of eEF2K activation. We discussed other possible contributions of eEF2K in the discussion.
Referee #2:
In The autoradiograms were performed four times and the quantifications are shown in Figure  4A . The representative autoradiograms were removed from the Figure and we now provide original source data with quantification of all the autoradiograms. In addition, we confirmed the data by monitoring protein synthesis upon NFR treatments by scintillation counting in both EEF2K WT and KO and eIF2aWT and S51A MEFs (New Figure 4B) .
B) As pointed out in the manuscript if the inhibition of translation was solely due to elongation changes there should be no difference in the heavy polysomes and indeed there should have been an increase in the heavy fractions on the polysomes as the mRNAs are stalled. I think that the unexpected effect is due to the fact that both initiation and elongation are inhibited by NFR. Indeed, it is shown in the EV figures that there is a significant phosphorylation of eIF2 alpha which would also inhibit initiation. To show that while both processes are inhibited it is elongation that drives the protein synthesis shutdown a couple more experiments are required. 1. Add NFR to cells that have been transfected with the dominant negative version of GADD34 (this will dephosphorylated eIF2 alpha), Then repeat the gradients and use met labelling to show that despite eIF2 activation this isn't sufficient to restore protein synthesis rates. 2. Add NFR in the presence of ISRIB, this should phenocopy the GADD34 experiment.
This is an important point that we addressed as follow: 1) As suggested, we used ISRIB to block the integrated stress response and monitored the polysomes profiles upon treatment with NFR or Tunicamycin (New Figure EV4A) . 2) We performed polysomal profiling as well as 35S-Methionine incorporation in eIF2aS51A and control cells (New Figure 4B and New Figure EV4 ). The S51A mutation impaires completely eIF2a -mediated initiation block. We found that the integrated stress response contributed to overall inhibition of protein synthesis, however the polysomal profiling indicated that in absence of ISR, NFR still triggered a decrease of the polysomal fraction and increased the subpolysomes in an eEF2K-dependent manner ( Figure 4C ). Morever as suggested by reviewer 1 we confirmed that eEF2K decreased elongation rates upon treatement with NFR (New Figure 4D) . In summary our data show that eEF2K engagement by NFR leads to a decrease in elongation and a decrease in the polysomal fraction. It is therefore possible that eEF2K may impact other translation steps beyond elongation. Both its effects on elongation and possibly initiation may contribute to eEF2K anti-tumoral effect.
Minor point Please don't use protein translation. proteins are synthesised and mRNAs are translated. e.g.in the abstract "protein translation elongation rates' should read mRNA translation elongation rates etc,
We thank the reviewer for pointing out this error.
Referee #3:

In this study, Dr. Martinon and colleagues have investigated the oncology mechanism of action of the drug Nelfinavir and show that it includes the ability to activate eEF2K, leading to the phosphorylation of eEF2 which causes its inactivation. eEF2 participates in translation elongation but is inhibited when phosphorylated and thereby slows translation elongation rates. Much of the study is well done but there are several issues that need to be resolved as outlined below.
The major criticism of the work presented is that it does not connect he established activity of Nelfinavir directly to molecular mechanisms. Early on in the study the authors show that drug treatment strongly reduces the mRNA levels for eEF2K (Figure 1C), but they never revisit this important effect and never explain or investigate how it occurs. This appears to be a major effect of the drug yet it is never followed up.
This comment is related to the second question of the Referee 1. As mentioned above we clarified this in the text. In the first part of the paper we selected clones that were resistant to NFR. These clones had decreased eEF2K expression and signaling. Among the cells selected in presence of NFR only a few clones grew. We present new data showing that eEF2K downregulation is stable and maintained after NFR washout at least in two out of three representative clones (New Fig EV1) , indicating that eEF2K downregulation cannot be recapitulated by direct treatment with NFR but possibly represents a mechanism of resistance. Moreover, we do not observe significant eEF2K down regulation as a direct effect of short-term treatment with NFR (see for example Figure 2B , parental cells treated 6 h with increasing doses of NFR). We therefore focused the study on understanding the role of eEF2K in NFR responses. We revised the result section to clarify this point.
It is unclear why any of the traditional signaling to eEF2K protein would be expected to alter its mRNA levels. Why was the mTOR pathway explored? How does this connect?
We don't know if the observed decrease in eEF2K mRNA level in NFR-resistant clones is induced by adaptation mechanisms to the drug or if it relies on a selection mechanism allowing survival of only the cells that have intrinsic low expression of eEF2K. Therefore, we performed long-term NFR washout experiment. The result indicates that the mechanism engaged by the clones to bypass eEF2K-mediated toxicity are multiple and can be maintained even in absence of NFR. Nevertheless, our main observation is that NFR treatment triggered a strong activation of eEF2K activity leading to increase in eEF2 phosphorylation (without impacting on eEF2K level as mentioned above). Then, we interrogated the possibility that NFR could trigger this pathway by impacting on mTOR or AMPK activity. However we found that these two well-characterized eEF2K regulating pathways are not required for NFR-mediated eEF2K activation. As mentioned by reviewer 1, we should have discussed other published mechanisms that could regulate eEF2K activity and accordingly, we added this in the revised manuscript.
The fact that eF2 phosphorylation does not alter polysome profiles significantly at the level of elongation still needs explanation. The suggestion that an alternate activity of eF2 phosphorylation, the splitting of 80S ribosomes (which are often inactive) does not directly address the mechanism of action of the drug nor how it would reduce cell proliferation.
We clarified the mechanisms of NFR mediated regulation of translation in the revised Figure 4 and new EV4. As described above, we show that eEF2K contributes to both decreased elongation rates and decreased polysomal fractions. This suggests a new fonction of eEF2K beyond elongation. We agree with the reviewer that this study opens new questions that remain to be adressed, including the question of how eEF2K is engaged upon treatment with NFR and how eEF2K mediated translational reprograming affects tumor growth. We tried to better highligth these points in the discussion.
The authors need to more fully explain how they conducted drug resistance studies. Important details are not described. How long was the election for, at what doses? How was it ascertained that resistance arose? Were these clonal or mixed populations of cells?
We clarified this in the text. Clonal populations were used. Resistance was ascerted by the ability of the clones to survive and grow in presence of 10 mM NFR, which is a dose killing more than 99% of the population after 1 week of culture and 3 passages. Moreover, 10 mM is the maximal dose that allows us to isolate such resitant clones; indeed, we tried to increase NFR to 12.5 mM but failled to isolate cells able to grow in this condition.
Cited Reference Thank you for the submission of your revised manuscript to our editorial offices. We have now received the enclosed reports on it. As you will see, while referee 3 is satisfied with the revision, reviewer 1 still raises concerns about the polysome traces and ribosome half transit times and feels that additional analyses and the display of the raw data underlying the figures is needed for the reader and the reviewers to be able to judge the data. Please note that referee 2 also comments on this issue. Therefore, I would kindly ask you to address the remaining issues along the lines suggested by reviewer 1 before submitting the final version of the study. Once you have done so I would run your new data by reviewer 1 for a final assessment.
I look forward to seeing the final version of your manuscript when it is ready.
REFEREE REPORTS
Reviewer 1 comments on rebuttal:
The revised manuscript submitted by De Gassart et al has addressed many of the minor points raised during the first round of review. However major concerns are still present following the resubmission. Of most concern is the quality of the ribosome half transit times provided. The experiments attempted would be the perfect illustration of the role of NFR in the slowing of translation elongation, with appropriate controls chosen in the form of CHX and starvation. Unfortunately the half transit time values stated above the graphs included in Figure 4D are very different to what can be easily interpreted from the graphs themselves. The difference between the intercepts of the backward projected PMS and PRS lines on the x axis is what is defined as the ribosome half transit time. Thus the values stated above the graphs in Figure 4D can be verified by simply integrating the data presented in the graphs by eye. Doing so gives times that are consistently shorter than those stated -indeed for 3 of the graphs the half transit time seems to be 0 seconds. Therefore this data needs to be reanalysed or carried out again. The raw data should also be made available.
Secondly, the data provided in the rebuttal regarding the 40S subunit's omission is not sufficient to convince the reader that the P/S ratio has been appropriately calculated. In fact they are convincing evidence that the P/S ratio cannot be interpreted from the traces. If the 40S subunit cannot be resolved (presumably from the initial 'free RNA' peak) then the P/S cannot be calculated and repeat experiments need the carried out. The authors need to provide the full polysome traces for the data presented in figure 3C , annotated with the areas of the trace considered subpolysomal and polysomal. The reviewers can then make their own mind up as to whether the integration was done correctly.
Referee #2:
I still don't think that the polysome profiles make complete sense, even with the additional experiments and there is certainly something else going on here with this drug. However, the overall story is very interesting and the authors have done a good job in addressing my concerns and the experiments I requested have been carried out.
In my opinion this is now suitable for publication in EMBOR.
Referee #3:
The authors have now resolved all outstanding issues raised by this reviewer.
2nd Revision -authors' response 12 July 2016
Thank you for conveying the positive comments of the three reviewers and for letting us the opportunity to address the technical issues raised by reviewer 1. I'm submitting the revised version of our manuscript entitled "Promoting cell death and antitumor activity by increasing eEF2K activation" (MS#: EMBOR-2016-42194) for your consideration for publication in EMBO reports. We clarified the analysis performed for the ribosome half transit times and the polysomal traces in the new version. Moreover as suggested by the reviewer we also provide the raw data underlying the figures for the reader and the reviewers to be able to better judge the data. I believe that our results convincingly show that Nelfinavir activates eEF2K to promote anti-tumoral activity. Changes to the manuscript text have been noted in red in the uploaded marked-up version.
Please let us know if we need to provide additional information as you reconsider the revised manuscript Point-by-point reply to the specific points raised by the Editor and Reviewers:
1) Editor Comments:
Thank you for the submission of your revised manuscript to our editorial offices. We have now received the enclosed reports on it. As you will see, while referee 3 is satisfied with the revision, reviewer 1 still raises concerns about the polysome traces and ribosome half transit times and feels that additional analyses and the display of the raw data underlying the figures is needed for the reader and the reviewers to be able to judge the data. Please note that referee 2 also comments on this issue. Therefore, I would kindly ask you to address the remaining issues along the lines suggested by reviewer 1 before submitting the final version of the study. Once you have done so I would run your new data by reviewer 1 for a final assessment.
We addressed the technical issues raised by reviewer 1 as detailed below. We clarified the analysis performed for the ribosome half transit times and the polysomal traces both in the figure and in the legend in the new version of the manuscript. Moreover we also provide the raw data underlying the figures for the reader and the reviewers to be able to better judge the data.
As pointed by reviewer 2, if Nelfinavir-mediated inhibition of protein synthesis is very robust, we agree that there is certainly something else going on with this drug. Nevertheless, I believe that our results and the new version of the paper open a new window in the study of eEF2K function and convincingly show that Nelfinavirmediated eEF2K activation promote anti-tumoral activity.
2) Reviewer Comments:
The revised manuscript submitted by De Gassart et al has addressed many of the minor points raised during the first round of review. However major concerns are still present following the resubmission. Figure 4D are Figure 4D can be verified by simply integrating the data presented in the graphs by eye. Doing so gives times that are consistently shorter than those stated -indeed for 3 of the graphs the half transit time seems to be 0 seconds. Therefore this data needs to be reanalysed or carried out again. The raw data should also be made available.
Of most concern is the quality of the ribosome half transit times provided. The experiments attempted would be the perfect illustration of the role of NFR in the slowing of translation elongation, with appropriate controls chosen in the form of CHX and starvation. Unfortunately the half transit time values stated above the graphs included in
very different to what can be easily interpreted from the graphs themselves. The difference between the intercepts of the backward projected PMS and PRS lines on the x axis is what is defined as the ribosome half transit time. Thus the values stated above the graphs in
We thank the reviewer for pointing out these technical questions. We hope that the revised version and the new raw data will clarify the methodology used and will provide the readers with all the relevant information to better appreciate and repeat the data.
We performed the ribosome half transit time experiments using the methods derived from Fan and Penman (1). This experiment was performed very carefully and repeated many times in order to generate reliable data. The results showed that NFR significantly decreased elongation rates of mRNA translation. The method compares the incorporation of radioactive amino acids into total peptides (incomplete nascent peptide still bound to polysomes, plus completed released peptides; PMS line) to the incorporation into released peptides after removal of the polysomes by centrifugation (PRS line). We set-up this technique carefully in the lab based on literature and advice we received from colleagues in the field. We also verified our protocols and analysis using appropriate controls that are known to affect elongation including CHX, and starvation.
In theory this time course method is independent on the rate of initiation and the measure of 35S-Methionine incorporation into the PMS and PRS should graph as two parallel lines as initially reported by Fan and Penman. When the lines are parallel, the displacement in time between the PMS and PRS should be the same independently of where we place the x axis along the y axis. Therefore the RTT is generally extrapolated by measuring the theoretical measurement at 0 CPM (i.e. where the lines cross the x axis). However, by performing this experiment, we consistently found that in our system the lines of the plots are not parallel possibly reflecting some regulatory loops or incomplete recovery of released labeled polypeptides (PRS) in the supernatant. Similar profiles are shown in a number of published reports (see for example (2) (3) (4) ).
Because the lines are not parallel, the displacement of the curves between PMS and PRS (that will give the measured RTT) will change through time and in some cases, lines will cross each other before reaching x axis. We therefore standardized the measure to the first point that gives us an actual data in the linear part of the curve. We measured the amount of incorporation at 5 min (300sec) of adding the radioactive amino acid in the PMS fraction and move the x axis to that value to measure the displacement between the PMS and PRS lines. The results obtained were very reproducible and consistent, compared to the estimation at 0 CPM. Although we agree that the non-parallel nature of the plot might affect the measurements, we believe that its interpretation is compatible with the protocol and analysis from the original Fan and Penman approach and that it does not change the overall conclusion that elongation rates are altered upon NFR treatment. Most importantly all samples were analyzed using the same protocol and therefore can be compared. We also performed an additional measurement at 600sec that gave similar results and are included in the new raw data file.
We described this analysis in the methods, but we agree with the reviewer that the reading of the figure was confusing. In the new version of the manuscript, we illustrated this better by only including the measured part of the curve. We included in the figure legend that the data indicates the measurement at 300sec.
As requested by the reviewer we also added the raw data of the experiment that includes 4 different experiments for NFR treatment in EEF2K WT and KO MEFs and the calculation of the PMS to PRS displacement at different times of 35S-Methionine incorporation. Improved description of the analysis and raw data will help the reader to interpret our results and overall improves the quality of this figure. figure 3C , annotated with the areas of the trace considered subpolysomal and polysomal. The reviewers can then make their own mind up as to whether the integration was done correctly.
In order to clarify this point, we included now the full polysomal trace in figure 4C and highlighted the area used to calculate the P/S ratio. We also included in the new version of the manuscript raw data for that figure showing individual polysomal trace for each condition together with the area used to calculate P/S ratio and the final result obtained after normalization to the untreated condition. The same model was used to analyse polysomal trace of all experiments presented in our study. The data previously provided in the letter regarding the presence of the 40S subunits in the fraction 7 of the polysomal trace was also added in this raw data file. These data indicate that the 40S was included in the analysis.
We hope that these clarifications together with the extensive polysomal analysis that we performed in this study using previously characterized drugs such as tunicamycin or CHX that affect respectively translation initiation and elongation will allow to validate our experimental set-up and convince the reader of that NFR affects polysomal distribution.
Referee #2:
I still don't think that the polysome profiles make complete sense, even with the additional experiments and there is certainly something else going on here with this drug. However, the overall story is very interesting and the authors have done a good job in addressing my concerns and the experiments I requested have been carried out. In my opinion this is now suitable for publication in EMBOR.
We agree that there is something unique going on with NFR and/or eEF2K activation and the regulation mRNA translation. The polysomal profiles are not compatible with an exclusive role of eEF2K in protein elongation, as we would have expected. In contrast the data suggest an additional function during initiation.
We appreciate the positive assessment of the overall study. Thank you for the submission of your revised manuscript to our editorial offices. We have now received the enclosed report on it. As you will see, the referee finds the manuscript suitable for publication in EMBO reports.
Before we can proceed with the formal acceptance of your manuscript, I would like to ask you for some further minor revisions.
Supplementary/additional data: The Expanded View format, which will be displayed in the main HTML of the paper in a collapsible format, has replaced the Supplementary information. You can submit up to 5 images as Expanded View. Please follow the nomenclature Figure EV1 , Figure EV2 etc. The figure legend for these should be included in the main manuscript document file in a section called Expanded View Figure The current Appendix Table 1 needs to be renamed to Dataset EV1 and please provide a legend for that (the current headline seems to be cut).
The current I look forward to seeing a revised version of your manuscript when it is ready. Please let me know if you have questions or comments regarding the revision.
REFEREE REPORTS
The analysis of the RTTs is not particularly orthodox but it illustrates the point. This is now acceptable for publication. Author made requested editorial changes. Do the data meet the assumptions of the tests (e.g., normal distribution)? Describe any methods used to assess it.
Is there an estimate of variation within each group of data?
Is the variance similar between the groups that are being statistically compared?
Yes. Every figure indicates the numer of experiments done. Statistics are described in legend and in the material and methods section. Differences were considered significant at a p------value of 0.05 or less.
The methods used are standard in the field. It is not possible to test for normal distribution in our experimental conditions.
Yes. We provide the standard error of the mean for all numerical data.
NA YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND ê
The number of experiments were performed according to the standards of the field.
Due to the normal variability of tumor growth from one mouse to another and to obtain relevant statistical analysis, each group contains at least 5 mice for experiments using tumor growth as read out. We calculate the number of mice to use in each experiment in order to have informative and conclusive data: Each experiments will have to be repeated once to confirm that the response induced is not due to extra factors. Because of the number of mice per group in each experiment, two repeats will be enough to validate the results and make definitive conclusions. For animal studies we pre--established exclusion criteria as data that deviates from the mean by more than three times the standard deviation.
NA
After Tumor cells injections, mice were randomly distributed in each group.
The investigators were not blinded to allocation during experiments and outcome assessment.
definitions of statistical methods and measures:
1. Data the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified
Please fill out these boxes ê (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
B--Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
the exact sample size (n) for each experimental group/condition, given as a number, not a range; a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.
a statement of how many times the experiment shown was independently replicated in the laboratory.
Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
Please ensure that the answers to the following questions are reported in the manuscript itself. We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
In This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. These guidelines are consistent with the Principles and Guidelines for Reporting Preclinical Research issued by the NIH in 2014. Please follow the journal's authorship guidelines in preparing your manuscript.
